Anti-SARS-CoV-2 Monoclonal Antibodies AZD5156

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A combination of two neutralizing human monoclonal antibodies, cilgavimab, a neutralizing human monoclonal antibody directed against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike (S) protein, and AZD3152, a long-acting neutralizing human monoclonal antibody directed against SARS-CoV-2, derived from B-cells of convalescent patients with SARS-CoV-2 infection, that can potentially be used for passive immunization against Coronavirus disease 2019 (COVID-19). Upon administration of anti-SARS-CoV-2 monoclonal antibodies AZD5156, cilgavimab specifically targets and binds to the SARS-CoV-2 S protein, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. Anti-SARS-CoV-2 monoclonal antibody AZD3152 also neutralizes SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2. S protein, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.

**Synonyms:** - AZD 5156 - AZD-5156 - AZD1061 Plus AZD3152 - AZD1061/AZD3152 - AZD5156 - Cilgavimab Plus AZD3152 - Cilgavimab/AZD3152